Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,580 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes (T1D) Clear all
Active, not recruiting Phase 3 Interventional

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

NCT07076199
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin icodec, Insulin glargine, Insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
103
States / cities
Cullman, Alabama • Concord, California • Escondido, California + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 7:56 AM EDT
Terminated Phase 3 Interventional

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

NCT00751842
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
rhGAD65, Placebo
Drug
Lead sponsor
Diamyd Therapeutics AB
Industry
Eligibility
10 Years to 20 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 15, 2026, 7:56 AM EDT
Not yet recruiting Phase 2 Interventional

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems

NCT07616206
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Cadisegliatin 800 mg QD, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

Evaluation of an Ascensia Blood Glucose Meter and App System

NCT02568384
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Onyx BG Meter / App System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Phase 4 Interventional Results available

Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus

NCT00607087
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin glulisine, Insulin lispro, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional

Telemedicine for Reach, Education, Access, and Treatment for Diabetes Self-Management Education and Support

NCT06626347
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
TREAT-ED Virtual Group Diabetes Self-Management Education and Support
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 26 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Phase 3 Interventional

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

NCT00424333
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled human insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
30
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

Feasibility Trial of a Mindfulness Based Intervention in Youth With Type 1 Diabetes

NCT05268393
View directory record Official record
Conditions
type1diabetes
Interventions
BREATHE-T1D
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet

NCT03443180
View directory record Official record
Conditions
Type1diabetes
Interventions
Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 23 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

Two Way Crossover Closed Loop Study MPC vs FMPD

NCT04771403
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor

NCT01112696
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Sensor wear
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Escondido, California • Santa Barbara, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 15, 2026, 7:56 AM EDT
Recruiting Phase 2 Interventional

Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes

NCT07186660
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus, Insulin, Ketones, Cardiovascular Health
Interventions
CIR-0602K, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 15, 2026, 7:56 AM EDT
Withdrawn Phase 3 Interventional

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

NCT04254380
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Lispro Injection, Humalog
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anaheim, California • Fresno, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 15, 2026, 7:56 AM EDT
Recruiting Not applicable Interventional

C-Carbs: A CGM-guided Approach to Teaching Carb Awareness

NCT07807280
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
C-Carbs Program
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 7:56 AM EDT
Completed No phase listed Observational

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

NCT06177691
View directory record Official record
Conditions
Type1 Diabetes
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 7:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hippocampal Metabolism and Function in Patients With Type 1 Diabetes

NCT01852968
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
20 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 15, 2026, 7:56 AM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT06258304
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor Malignancies
Interventions
GIGA-564
Drug
Lead sponsor
GigaGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 15, 2026, 7:56 AM EDT
Suspended Not applicable Interventional

Avatar-based Social Physical Activity

NCT05662826
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Avatar-based Social Physical Activity
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 15, 2026, 7:56 AM EDT
Enrolling by invitation Not applicable Interventional

The ELG Analysis of Glucose a Correlational to Blood Glucose Assay

NCT05055804
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
ELG
Device
Lead sponsor
XP Technology, LLC
Other
Eligibility
25 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Springdale, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

NCT03211858
View directory record Official record
Conditions
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions
Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

NCT05403502
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
t:slim X2 insulin pump with Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Orange, California • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 15, 2026, 7:56 AM EDT
Active, not recruiting Phase 4 Interventional

Dapagliflozin Plus Pioglitazone in T1DM

NCT03878459
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Pioglitazone 45 mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 15, 2026, 7:56 AM EDT
Completed Not applicable Interventional Results available

Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study

NCT02877680
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
T1Doing Well
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 15, 2026, 7:56 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

NCT00287066
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Human Insulin, Regular Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 15, 2026, 7:56 AM EDT